Bicocca Open Archive

Logo unimib boa
CAIROLI, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.884
AS - Asia 1.216
NA - Nord America 1.181
SA - Sud America 43
AF - Africa 13
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.343
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.155
IE - Irlanda 894
HK - Hong Kong 868
IT - Italia 565
CN - Cina 232
DE - Germania 100
GB - Regno Unito 95
SE - Svezia 61
FI - Finlandia 43
IN - India 42
BR - Brasile 36
ES - Italia 24
UA - Ucraina 21
CA - Canada 16
FR - Francia 14
JP - Giappone 12
CH - Svizzera 10
MX - Messico 10
NL - Olanda 10
VN - Vietnam 10
BE - Belgio 8
DK - Danimarca 8
SA - Arabia Saudita 8
HR - Croazia 7
HU - Ungheria 7
ID - Indonesia 6
TR - Turchia 6
IL - Israele 5
NP - Nepal 5
AU - Australia 4
CO - Colombia 4
GR - Grecia 4
IR - Iran 4
MA - Marocco 4
PL - Polonia 4
SG - Singapore 4
TH - Thailandia 4
CZ - Repubblica Ceca 3
PH - Filippine 3
ZA - Sudafrica 3
AM - Armenia 2
CL - Cile 2
EG - Egitto 2
PK - Pakistan 2
RU - Federazione Russa 2
SI - Slovenia 2
TW - Taiwan 2
UG - Uganda 2
AR - Argentina 1
BG - Bulgaria 1
EU - Europa 1
GH - Ghana 1
KR - Corea 1
NZ - Nuova Zelanda 1
RO - Romania 1
TN - Tunisia 1
Totale 4.343
Salva come PNG Salva come JPEG
Città #
Hong Kong 865
Dublin 844
New York 388
Ashburn 180
Milan 134
Ann Arbor 124
Beijing 112
Frankfurt am Main 72
Fairfield 46
Seattle 43
Chandler 41
Turin 37
Helsinki 34
Desio 33
Shanghai 33
London 30
Rome 26
Washington 25
São Paulo 24
Houston 22
Jacksonville 19
Princeton 18
Wilmington 18
Kilburn 17
Assago 16
Dearborn 16
Los Angeles 15
Woodbridge 13
Cambridge 12
Phoenix 12
Bologna 11
Boardman 10
Naples 10
Altamura 9
Lawrence 9
San Diego 9
Carate Brianza 8
Chiswick 8
Guadalajara 8
Mumbai 8
Nanjing 8
Debrecen 7
Hyderabad 7
Orbassano 7
Zagreb 7
Changsha 6
Lappeenranta 6
Madrid 6
Amsterdam 5
Brescia 5
Brugherio 5
Brussels 5
Chengdu 5
Corsico 5
Istanbul 5
Rocca Canavese 5
San Jose 5
Taiyuan 5
Tel Aviv 5
Veniano 5
Verona 5
Biratnagar 4
Delhi 4
Guangzhou 4
Hangzhou 4
Montreal 4
Padova 4
Palermo 4
Paris 4
Perugia 4
Shijiazhuang 4
Torre Annunziata 4
Aalst 3
Abbiategrasso 3
Alatri 3
Americana 3
Arezzo 3
Asahikawa 3
Barcelona 3
Bari 3
Beauharnois 3
Bergamo 3
Burlington 3
Cantu 3
Central 3
Changchun 3
Falls Church 3
Jalgaon 3
Johannesburg 3
Lachine 3
Monza 3
Mountain View 3
New Delhi 3
Polignano a Mare 3
Pune 3
Riyadh 3
Sedico 3
Shiraz 3
Siziano 3
Sydney 3
Totale 3.606
Salva come PNG Salva come JPEG
Nome #
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia 174
Assessing eligibility for treatment in acute myeloid leukemia in 2023 167
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 145
RNA hyperediting and alternative splicing of hematopoietic cell phosphatase (PTPN6) gene in acute myeloid leukemia 136
The role of quantitative polymerase chain reaction in the management of follicular lymphoma patients 124
Impact of serial echocardiography in the management of primary cardiac lymphoma 118
KIT activating mutations: Incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication 98
Current Treatment Options and the Role of Functional Status Assessment in Classical Hodgkin Lymphoma in Older Adults: A Review 65
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 53
Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities 44
Use of Sorafenib in FLT3-Mutant Myeloid Sarcoma: A Case Report 44
Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients 38
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients with Lymphoproliferative Disorders on BTKi 36
IN ADULT ACUTE MYELOID LEUKEMIA (AML) PERIPHERAL BLOOD MEASURABLE RESIDUAL DISEASE (MRD) BY FLOW CYTOMETRY (FC) IS FEASIBLE AND IS PROGNOSTICALLY RELEVANT 35
How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia 33
A novel start-loss mutation of the SH2B3 gene in a family with myeloproliferative neoplasms 33
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 30
Arg expression studied in normal human leukocytes and in leukemic cells by RT-PCR 30
"Efficient Strategies for the Reuse of Surgical and FFP2/ KN95 Face Masks during the COVID-19 Pandemic: Home-Made and Ecological Choices for the Community" 28
Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 28
MIS-A: Beware of non-lymphoma 27
Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial 26
A phase I/IIa clinical trial of autologous hematopoietic stem cell transplantation in amyotrophic lateral sclerosis 25
Detection by polymerase chain reaction of BCR/ ABL transcripts in myeloproliferative diseases at time of diagnosis and for monitoring chronic myelogenous leukaemia patients after bone marrow transplantation 24
RISK-ADAPTED, MRD-DIRECTED THERAPY FOR YOUNG ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: RESULTS OF THE AML1310 TRIAL OF THE GIMEMA GROUP 24
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial 24
Occurrence of L1M Elements in Chromosomal Rearrangements Associated to Chronic Myeloid Leukemia (CML): Insights from Patient-Specific Breakpoints Characterization 24
Prognostic significance of CD33, CD34 and CD117 expression on bone marrow blasts of patients with Myelodysplastic syndromes 24
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort 23
ACUTE PROMYELOCYTIC LEUKEMIA - COMPLETE REMISSION AND BONE-MARROW TRANSPLANTATION FOLLOW-UP MONITORED BY POLYMERASE CHAIN-REACTION 23
Quantification of 1,3-β-d-glucan by Wako β-glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study 23
Intrahospital COVID-19 infection outbreak management: Keep calm and carry on 23
Saccharomyces cerevisiae fungemia with granulomas in the bone marrow in a patient undergoing BMT 22
Outcome of Transformed Marginal Zone Lymphomas Treated in the Rituximab Era 22
Gastrointestinal Kaposi's Sarcoma in a Woman with Selective IgA Deficiency and prior Immunosuppressive therapy for Idiopathic Thrombocitopenioc Purpura 22
Danazol Treatment for Thrombocytopenia in Myelodysplastic Syndromes: Can an "Old-fashioned" Drug be Effective? 22
A phase I/II study of NMS-03592088, a FLT3, KIT and CSF1R inhibitor, in patients with relapsed or refractory AML or CMML 22
Plasma cell-directed therapy and anti-HLA antibody production: A successful combination? 21
Dual antiviral therapy in haematological patients with protracted SARS-CoV-2 infection 21
Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) 20
Detection of c-KIT antigen (CD117) and c-kit mRNA in acute leukemia 20
Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study 19
Myeloma’s multiple morphologies 19
Trisomy 4 and c-kit mutation in a t(8;21) myeloid leukemia with mast cell involvemen 19
"MOLTO", A MULTICENTER, OPEN LABEL, UNCONTROLLED, PHASE II CLINICAL TRIAL ON VENETOCLAX, ATEZOLIZUMAB, OBINUTUZUMAB (AVO) COMBINATION IN RICHTER TRANSFORMATION: SAFETY INTERIM ANALYSIS 19
Corrigendum: Intronless WNT10B-short variant underlies new recurrent allele-specific rearrangement in acute myeloid leukaemia 19
PML/RAR alpha transcripts monitored by polymerase chain reaction in acute promyelocytic leukemia during complete remission, relapse and after bone marrow transplantation 19
Identification of genes differently expressed between bone marrow CD34+/LIN-cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs 12 months of first-line nilotinib treatment 19
Quantitative PCR survey of chronic myelogenous leukemia (CML) transplanted patients 19
IDENTIFICAZIONE DI MIRNA E GENI TARGET NELL’ANALISI TRASCRITTOMICA DELLE CELLULE CD34+/LIN- DI PAZIENTI CON LEUCEMIA MIELOIDE CRONICA IN FASE CRONICA DOPO 12 MESI DI TERAPIA CON NILOTINIB 19
High dose etoposide and cyclophosphamide (HD-VP/CTX) as salvage treatment for all patients 19
c-kit activating mutations and mast cell proliferation in human leukemia [4] 19
VENETOCLAX IN MULTI-RELAPSED MANTLE CELL LYMPHOMA PATIENTS: A REAL-LIFE MULTICENTRIC EXPERIENCE 18
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia 18
Complications at insertion of untunnelled central venous catheters (UCVCs) in leukemic patients at a high risk of hemorrhage 18
SEVERE HIV-RELATED THROMBOCYTOPENIA (HIV-REL TP) - COULD SPLENECTOMY IMPROVE SURVIVAL 18
C-Kit point mutations in core binding factor leukemias: correlation with white blood cell count and the white blood cell index 18
Fungal infections in hematologic neoplasms: Autopsy findings 18
Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H 18
PH plus STEM CELLS (SCS) IN CHRONIC MYELOID LEUKEMIA (CML): TO ERADICATE OR NOT TO ERADICATE, THIS IS THE QUESTION 18
Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy 18
Cytomegalovirus and Epstein-Barr Virus DNA Kinetics in Whole Blood and Plasma of Allogeneic Hematopoietic Stem Cell Transplantation Recipients 18
Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome 17
Invasive aspergillosis in hematological patients: Clinical features, microbiological findings and response to therapy 17
Bone Marrow Fibrosis and Early Hematological Response as Predictors of Poor Outcome in Azacitidine Treated High Risk-Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia 17
The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenstrom's Macroglobulinemia 17
PLASMA VON-WILLEBRAND-FACTOR MULTIMERIC ANALYSIS IN AUTOLOGOUS (ABMT) AND ALLOGENIC BONE-MARROW TRANSPLANTATION (BMT) 17
Limited feasibility of double transplant program: A multicenter study on 151 multiple myeloma patients aged <= 65 years 17
Validation of the "fitness criteria" for the treatment of older patients with acute myeloid leukemia: A multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (REL) 17
Molecular follow-up with qualitative and competitive PCR in patients affected by follicular lymphoma before and after auto or allo stem cell transplantation 17
Total serum tryptase: a predictive marker for KIT mutation in acute myeloid leukemia 17
Acute leukemia and high-risk myelodysplastic syndromes in hiv positive patients: 25-years' experience of the rete ematologica lombarda (REL) 17
Is HBV prophylaxis required during CLL treatment with ibrutinib? 17
Multidimensional Results and Reflections on CAR-T: The Italian Evidence 17
Prognostic value of circulating CD34+ cells in myelodysplastic syndromes 17
CLINICAL RELEVANCE OF RECURRENT ALLELE-SPECIFIC RECOMBINATION EXPRESSING THE WNT10BIVS1 ALLELE VARIANT IN ACUTE MYELOID LEUKEMIA 17
Prevalence and prognostic impact of KIT mutations in acute myeloid leukaemia with inv(16). A retrospective study 17
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia 16
A Case of Blastic Plasmacytoid Dendritic Cell Neoplasm Extensively Studied by Flow Cytometry and Immunohistochemistry 16
Identification of hematopoietic progenitor cell donor characteristics predicting successful mobilization: Results of an Italian multicenter study 16
Genes and Pathways Dysregulated by Nilotinib Treatment in Bone Marrow CD34+/Lin- Cells of Patients with Chronic-Phase Chronic Myeloid Leukaemia 16
SEQUENTIAL USE OF THROMBOPOIETIN RECEPTOR AGONISTS IN ADULT PRIMARY IMMUNE THROMBOCYTOPENIA PATIENTS: A RETROSPECTIVE COLLABORATIVE SURVEY FROM ITALIAN HEMATOLOGY CENTERS 16
ABNORMALITIES OF RED-BLOOD-CELLS (RBC) CYTOSKELETAL PROTEINS AND OF PLATELET (PLT) VON-WILLEBRAND-FACTOR (VWF) IN THE MYELODYSPLASTIC SYNDROMES (MDS 16
SOHO State of the Art Updates and Next Questions: What is Fitness in the Era of Targeted Agents? 16
VERY LONG-TERM RESULTS OF ALL-TRANS RETINOIC ACID AND ARSENIC TRIOXIDE IN NON-HIGH RISK ACUTE PROMYELOCYTIC LEUKEMIA: LATEST UPDATE OF THE ITALIAN-GERMAN APL0406 RANDOMIZED TRIAL 16
Abnormalities of cytoskeletal proteins of the red blood cells in myelodysplastic syndromes 16
OUTCOMES OF RELAPSED OR REFRACTORY AND NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA AFTER HYPOMETHYLATING AGENT AND VENETOCLAX. THE ITALIAN REAL-LIFE EXPERIENCE BEFORE PUBLIC HEALTH REIMBURSEMENT (AVALON STUDY) 16
Validation of ELN2017 Risk Stratification in a Post-Hoc Analysis of the Prospective Biomarker-Based Gimema AML1310 Protocol 16
C-kit mutations in core binding factor leukemias 16
Clofarabine-based chemotherapy as a bridge to transplant in the setting of refractory or relapsed acute myeloid leukemia, after at least one previous unsuccessful salvage treatment containing fludarabine: a single institution experience 15
Microarray of Bone Marrow CD34+/Lin- Cells from Patients with Chronic Myeloid Leukemia (CML) 15
Sequential subcutaneous administration of Campath-1H as treatment of minimal residual disease in CLL patients responding to fludarabine (FAMP) 15
In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation 15
Targeted Therapy in FLT3-ITD Positive Myeloid Sarcoma: Proof of Principle 15
Administration of plerixafor in poor mobilizers allows mobilization of haematopoietic progenitors: Clonogenic potential and engraftment analysis 15
Long Term Toxicity and Follow-up of Waldenstrom's Macroglobulinemia Patients after Salvage Treatment with Fludarabine Cyclophosphamide Rituximab or Bendamustine and Rituximab 15
GEP Analyses of Bone Marrow CD34+/Lin-Cells of Chronic Phase CML Patients at Diagnosis Identified Different Sets of Genes Associated to the Molecular Response after 3 and 6 Months of First-Line Nilotinib Treatment 15
Untunnelled central venous catheters in the treatment of acute leukemia 15
Impact of FLT3-ITD Mutations in Patients with Normal Karyotype Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation 15
Is Ashwell-Morell Receptor Mediated Hepatic Clearance of Platelet Clinically Relevant in Immune Thrombocytopenia (ITP)? a Retrospective Analysis of Platelet Kinetic Studies and Autoantibody Type Data 15
Totale 2.942
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.936
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.936
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201933 0 0 0 0 0 0 0 0 0 5 15 13
2019/202094 13 2 6 9 9 16 13 7 8 4 4 3
2020/2021141 3 3 40 14 15 11 12 12 14 6 3 8
2021/2022121 6 3 15 7 11 10 2 14 7 8 12 26
2022/20231.417 27 57 11 13 9 26 0 151 58 921 64 80
2023/20243.382 57 115 139 106 515 840 653 200 657 100 0 0
Totale 5.271